We are live on ! Find out more
AVTX icon

Avalo Therapeutics
AVTX

18 hedge funds and large institutions have $1.9M invested in Avalo Therapeutics in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

805% more capital invested

Capital invested by funds: $210K → $1.9M (+$1.69M)

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

50% more funds holding

Funds holding: 12 → 18 (+6)

10.93% more ownership

Funds ownership: 0.01% → 10.94% (+11%)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
18
Holders Change
+6
Holders Change %
+50%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$251K
2
SCM
Sio Capital Management
New York
+$54.7K
3
AAA
Affinity Asset Advisors
New York
+$53.9K
4
UBS Group
UBS Group
Switzerland
+$41.5K
5
ACM
ADAR1 Capital Management
Texas
+$32.3K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$74.1K
2
N
Natixis
France
-$11.3K
3
FIA
FNY Investment Advisers
New York
-$4K
4
TRCT
Tower Research Capital (TRC)
New York
-$679
5
Morgan Stanley
Morgan Stanley
New York
-$264
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
1
Ikarian Capital
Texas
$1.01M +$251K +46,648 New
SCM
2
Sio Capital Management
New York
$221K +$54.7K +10,151 New
AAA
3
Affinity Asset Advisors
New York
$218K +$53.9K +10,000 New
UBS Group
4
UBS Group
Switzerland
$168K +$41.5K +7,711 +385,550%
ACM
5
ADAR1 Capital Management
Texas
$131K +$32.3K +6,000 New
N
6
Natixis
France
$54.6K -$11.3K -2,092 -45%
BlackRock
7
BlackRock
New York
$46.2K -$74.1K -13,752 -87%
TRCT
8
Tower Research Capital (TRC)
New York
$35.7K -$679 -126 -7%
Royal Bank of Canada
9
Royal Bank of Canada
Ontario, Canada
$7K +$991 +184 +133%
BCV
10
Banque Cantonale Vaudoise
Switzerland
$2K +$1.82K +338 New
Morgan Stanley
11
Morgan Stanley
New York
$848 -$264 -49 -56%
Wells Fargo
12
Wells Fargo
California
$175 – – –
BNP Paribas Financial Markets
13
BNP Paribas Financial Markets
France
$87 +$22 +4 New
Group One Trading
14
Group One Trading
Illinois
$44 – – –
JP Morgan Chase
15
JP Morgan Chase
New York
$44 – – –
Osaic Holdings
16
Osaic Holdings
Arizona
$43 +$5 +1 +100%
OPTFSNA
17
Old Point Trust & Financial Services N A
Virginia
$22 +$5 +1 New
PA
18
Parallel Advisors
California
$22 +$5 +1 New
FIA
19
FNY Investment Advisers
New York
– -$4K -522 Closed
FHA
20
First Horizon Advisors
Tennessee
– -$9 -1 Closed

AVTX Hedge Fund Activity: Q1 2024 in Review

18 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2024, worth a combined $1.9M — up 805% from $210K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new AVTX positions and 2 closed out — a net gain of 6 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Ikarian Capital, opening a new position worth an estimated $251K. The largest seller was BlackRock, cutting an estimated $74.1K.

  • 18 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2024, up from 12 in Q4 2023.
  • Funds reported $1.9M of Avalo Therapeutics stock for Q1 2024, up 805% quarter-over-quarter.
  • 8 funds opened new Avalo Therapeutics positions in Q1 2024 and 2 closed out, a net change of +6 holders.
  • The largest Avalo Therapeutics buyer in Q1 2024 was Ikarian Capital, an estimated $251K added.
  • The largest Avalo Therapeutics seller in Q1 2024 was BlackRock, an estimated $74.1K sold.

Based on aggregated 13F filings for Q1 2024.